Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

Autor: Amy S. Paller, Carsten Flohr, Lawrence F. Eichenfield, Alan D. Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R. Natalie, Claudia Rodriguez Capriles, Evangeline Pierce, Sarah Reifeis, Renata Gontijo Lima, Clara Armengol Tubau, Vivian Laquer, Stephan Weidinger
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Dermatology and Therapy, Vol 13, Iss 7, Pp 1517-1534 (2023)
Druh dokumentu: article
ISSN: 2193-8210
2190-9172
DOI: 10.1007/s13555-023-00942-y
Popis: Abstract Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease. Lebrikizumab, a monoclonal antibody targeting interleukin (IL)-13, demonstrated clinical benefit in previous Phase 3 trials: ADvocate1 (NCT04146363), ADvocate2 (NCT04178967), and ADhere (NCT04250337). We report 52-week safety and efficacy outcomes from ADore (NCT04250350), a Phase 3, open-label study of lebrikizumab in adolescent patients with moderate-to-severe AD. The primary endpoint was to describe the proportion of patients who discontinued from study treatment because of adverse events (AEs) through the last treatment visit. Methods Adolescent patients (N = 206) (≥ 12 to
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje